检验医学 ›› 2022, Vol. 37 ›› Issue (9): 877-881.DOI: 10.3969/j.issn.1673-8640.2022.09.017
收稿日期:
2021-03-15
修回日期:
2021-11-22
出版日期:
2022-09-30
发布日期:
2022-10-25
通讯作者:
赵爱光
作者简介:
赵爱光,E-mail: aiguangzhao@qq.com。基金资助:
WANG Rui, LI Zhaoyan, ZHAO Aiguang()
Received:
2021-03-15
Revised:
2021-11-22
Online:
2022-09-30
Published:
2022-10-25
Contact:
ZHAO Aiguang
摘要:
胃癌是常见的恶性肿瘤之一,由于其具有高度异质性,患者5年生存率<30%,因此需要寻找新的、可靠的生物标志物来提高胃癌的早期诊断率和复发转移的预测准确率,从而更好地指导治疗,并改善预后。循环肿瘤DNA(ctDNA)是从凋亡坏死的肿瘤细胞中释放的游离DNA,携带与肿瘤相关的基因突变信息。ctDNA检测一般采用液体活检技术,可作为生物标记物对胃癌实施动态监测,具有安全、微创、方便、可重复等优点,在早期诊断、病情监测及个性化治疗方面具有重要的临床意义。文章对ctDNA的生物学特征、检测方法及其在胃癌诊断、治疗及预后评估中的作用进行阐述,探讨ctDNA在胃癌中的临床应用价值。
中图分类号:
王芮, 李朝燕, 赵爱光. 循环肿瘤DNA检测在胃癌诊疗中的应用现状[J]. 检验医学, 2022, 37(9): 877-881.
WANG Rui, LI Zhaoyan, ZHAO Aiguang. Application of circulating tumor DNA detection in the diagnosis and treatment of gastric cancer[J]. Laboratory Medicine, 2022, 37(9): 877-881.
年份 | 文献 | 胃癌组/例 | 对照组/例 | 样本来源 | 变异方式 | 检测技术 | 突变基因 | 临床用途 |
---|---|---|---|---|---|---|---|---|
2015年 | MARTIGNANO等[ | 60 | 30 | 血浆 | 突变 | Droplet digital PCR | HER-2 | 治疗标志物 |
2015年 | KWAK等[ | 1 | 0 | 血浆、肿瘤组织 | 突变 | NGS panel | MET | 治疗标志物 |
2019年 | MATHAI等[ | 70 | 0 | 血浆、肿瘤组织 | 突变 | NGS panel | HER-2 | 治疗标志物 |
2019年 | MARTIGNANO等[ | 277 | 0 | 血浆、肿瘤组织 | 突变 | Mass ARRAY | TP53、PIK3CA、ERBB2、KRAS | 诊断/预后的生物标志物 |
表1 ctDNA识别胃癌分子标志物的相关研究概览
年份 | 文献 | 胃癌组/例 | 对照组/例 | 样本来源 | 变异方式 | 检测技术 | 突变基因 | 临床用途 |
---|---|---|---|---|---|---|---|---|
2015年 | MARTIGNANO等[ | 60 | 30 | 血浆 | 突变 | Droplet digital PCR | HER-2 | 治疗标志物 |
2015年 | KWAK等[ | 1 | 0 | 血浆、肿瘤组织 | 突变 | NGS panel | MET | 治疗标志物 |
2019年 | MATHAI等[ | 70 | 0 | 血浆、肿瘤组织 | 突变 | NGS panel | HER-2 | 治疗标志物 |
2019年 | MARTIGNANO等[ | 277 | 0 | 血浆、肿瘤组织 | 突变 | Mass ARRAY | TP53、PIK3CA、ERBB2、KRAS | 诊断/预后的生物标志物 |
[1] |
CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China,2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
DOI URL |
[2] |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
DOI URL |
[3] |
ZHENG R, ZENG H, ZHANG S, et al. Estimates of cancer incidence and mortality in China,2013[J]. Chin J Cancer, 2017, 36(1):66.
DOI URL |
[4] | 常敏, 张久聪, 周琴, 等. 胃癌流行病学研究进展[J]. 胃肠病学和肝病学杂志, 2017, 26(9):966-969. |
[5] |
WARTON K, SAMIMI G. Methylation of cell-free circulating DNA in the diagnosis of cancer[J]. Front Mol Biosci, 2015, 2:13.
DOI PMID |
[6] |
YANG S, TALBI A, WANG X, et al. Pharmacokinetics study of calf thymus DNA in rats and beagle dogs with(3)H-labeling and tracing method[J]. J Pharm Biomed Anal, 2014, 88:60-65.
DOI URL |
[7] | BRONKHORST A J, UNGERER V, HOLDENRIEDER S. The emerging role of cell-free DNA as a molecular marker for cancer management[J]. Biomol Detect Quantif, 2019, 17:100087. |
[8] |
KUSTANOVICH A, SCHWARTZ R, PERETZ T, et al. Life and death of circulating cell-free DNA[J]. Cancer Biol Ther, 2019, 20(8):1057-1067.
DOI PMID |
[9] |
ZHOU J, CHANG L, GUAN Y, et al. Application of circulating tumor DNA as a non-invasive tool for monitoring the progression of colorectal cancer[J]. PLoS One, 2016, 11(7):e0159708.
DOI URL |
[10] | 高明正, 张瑾, 潘云, 等. 循环肿瘤DNA研究进展及其临床应用现状[J]. 实用医药杂志, 2019, 36(7):664-668. |
[11] | PERKINS G, LU H, GARLAN F, et al. Droplet-based digital PCR:application in cancer research[J]. Adv Clin Chem, 2017, 79:43-91. |
[12] | MERKER J D, OXNARD G R, COMPTON C, et al. Circulating tumor DNA analysis in patients with cancer:American Society of Clinical Oncology and College of American Pathologists joint review[J]. J Clin Oncol, 2018, 36(16):1631-1641. |
[13] |
DEANS Z C, BUTLER R, CHEETHAM M, et al. IQN path ASBL report from the first European cfDNA consensus meeting:expert opinion on the minimal requirements for clinical ctDNA testing[J]. Virchows Arch, 2019, 474(6):681-689.
DOI URL |
[14] |
COHEN J D, LI L, WANG Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test[J]. Science, 2018, 359(6378):926-930.
DOI PMID |
[15] | LI Q, WU R, WU F, et al. KMT2D promotes proliferation of gastric cancer cells:evidence from ctDNA sequencing[J]. J Clin Lab Anal, 2021, 35(4):e23721. |
[16] |
GAO Y, ZHANG K, XI H, et al. Diagnostic and prognostic value of circulating tumor DNA in gastric cancer:a meta-analysis[J]. Oncotarget, 2017, 8(4):6330-6340.
DOI URL |
[17] |
LING Z Q, LV P, LU X X, et al. Circulating methylated XAF1 DNA indicates poor prognosis for gastric cancer[J]. PLoS One, 2013, 8(6):e67195.
DOI URL |
[18] |
UCHÔA GUIMARÃES C T, FERREIRA MARTINS N N, CRISTINA DA SILVA OLIVEIRA K, et al. Liquid biopsy provides new insights into gastric cancer[J]. Oncotarget, 2018, 9(19):15144-15156.
DOI PMID |
[19] |
CHEN M, ZHAO H. Next-generation sequencing in liquid biopsy:cancer screening and early detection[J]. Hum Genomics, 2019, 13(1):34.
DOI URL |
[20] |
QIU M Z, LI Q, WANG Z Q, et al. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients:a prospective cohort observation[J]. Int J Cancer, 2014, 134(10):2468-2477.
DOI URL |
[21] |
SHODA K, ICHIKAWA D, FUJITA Y, et al. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer[J]. Gastric Cancer, 2017, 20(1):126-135.
DOI PMID |
[22] |
WANG D S, LIU Z X, LU Y X, et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer[J]. Gut, 2019, 68(7):1152-1161.
DOI URL |
[23] |
PECTASIDES E, STACHLER M D, DERKS S, et al. Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma[J]. Cancer Discov, 2018, 8(1):37-48.
DOI PMID |
[24] | LIU Y, YANG M, JIANG T, et al. Quantitative analysis of HER2 amplification by droplet digital PCR in the follow-up of gastric cancer patients being treated with trastuzumab after surgery[J]. Gastroenterol Res Pract, 2019, 2019:1750329. |
[25] |
AGUILAR-MAHECHA A, JOSEPH S, CAVALLONE L, et al. Precision medicine tools to guide therapy and monitor response to treatment in a HER-2+ gastric cancer patient:case report[J]. Front Oncol, 2019, 9:698.
DOI URL |
[26] |
JIN Y, CHEN D L, WANG F, et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors[J]. Mol Cancer, 2020, 19(1):154.
DOI PMID |
[27] |
WANG Y, ZHAO C, CHANG L, et al. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer[J]. EBioMedicine, 2019, 43:261-269.
DOI PMID |
[28] |
SHAHJEHAN F, KAMATHAM S, KASI P M. Role of circulating tumor DNA in gastrointestinal cancers:update from abstracts and sessions at ASCO 2018[J]. Front Oncol, 2019, 9:358.
DOI URL |
[29] |
DU J, WU X, TONG X, et al. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification[J]. Oncotarget, 2017, 8(16):26281-26287.
DOI PMID |
[30] |
ZHANG C, CHEN Z, CHONG X, et al. Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies[J]. Clin Transl Med, 2020, 10(8):e254.
DOI PMID |
[31] | KIM Y W, KIM Y H, SONG Y, et al. Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer[J]. Exp Mol Med, 2019, 51(8):1-10. |
[32] |
LI J, LI Z, DING Y, et al. TP53 mutation and MET amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer[J]. PeerJ, 2021, 9:e11146.
DOI URL |
[33] |
MATHAI R A, VIDYA R V S, REDDY B S, et al. Potential utility of liquid biopsy as a diagnostic and prognostic tool for the assessment of solid tumors:implications in the precision oncology[J]. J Clin Med, 2019, 8(3):373.
DOI URL |
[34] |
KINUGASA H, NOUSO K, TANAKA T, et al. Droplet digital PCR measurement of HER2 in patients with gastric cancer[J]. Br J Cancer, 2015, 112(10):1652-1655.
DOI URL |
[35] |
KWAK E L, AHRONIAN L G, SIRAVEGNA G, et al. Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer[J]. Cancer Discov, 2015, 5(12):1271-1281.
DOI PMID |
[36] |
ROLFO C, CARDONA A F, CRISTOFANILLI M, et al. Challenges and opportunities of cfDNA analysis implementation in clinical practice:perspective of the International Society of Liquid Biopsy(ISLB)[J]. Crit Rev Oncol Hematol, 2020, 151:102978.
DOI URL |
[37] |
MARTIGNANO F. Cell-free DNA: an overview of sample types and isolation procedures[J]. Methods Mol Biol, 2019, 1909:13-27.
DOI PMID |
[1] | 周韵斓, 沈立松. 液体活检标志物在非小细胞肺癌中的临床应用和挑战[J]. 检验医学, 2023, 38(9): 807-811. |
[2] | 孙泽朋, 王洪彬, 王建东, 宋德伟, 肖鹏. 心肌损伤多肽和蛋白类标志物方法学分析和进展[J]. 检验医学, 2023, 38(8): 784-789. |
[3] | 张敏, 王彬宇, 迟伟群, 刘禹. 外泌体非编码RNA作为疾病诊断生物标志物的研究进展[J]. 检验医学, 2023, 38(6): 594-598. |
[4] | 高锋. 新型肿瘤标志物的临床应用——前景与挑战[J]. 检验医学, 2023, 38(4): 303-306. |
[5] | 刘瑞丽, 李兰军, 贾旻蕾, 王一惠, 郝维纳. 胃癌组织miR-7-5p、NOVA2表达与患者临床预后的相关性[J]. 检验医学, 2023, 38(4): 325-329. |
[6] | 吴炯, 胡嘉华, 施美芳, 刘涛, 戴洁, 卢忻怡, 邹政. 前列腺癌生物标志物研究进展[J]. 检验医学, 2023, 38(2): 190-195. |
[7] | 刘庆阳, 袁建明, 夏进军, 姜风英, 王秋波, 王晓明. 基于GEO数据库和临床样本验证CXCL9作为类风湿关节炎生物标志物的研究[J]. 检验医学, 2023, 38(12): 1121-1129. |
[8] | 周福荣, 李龑杼, 刘勇敢. lncRNA SNP在结直肠癌易感性预测和预后评估中的应用[J]. 检验医学, 2023, 38(12): 1206-1210. |
[9] | 陈馨宁, 黄斐, 姜惠琴, 沈敏娜, 潘柏申, 王蓓丽, 郭玮. 非小细胞肺癌患者血浆EGFR基因c.2572_2573delinsAG位点突变1例报道[J]. 检验医学, 2023, 38(10): 1003-1005. |
[10] | 郭霜, 刘红莉, 李娅. EB病毒相关胃癌迁移、侵袭相关miRNA和lncRNA研究进展[J]. 检验医学, 2023, 38(10): 987-996. |
[11] | 鲁启源, 卢建华. 人工关节假体周围感染诊断生物标志物研究进展[J]. 检验医学, 2023, 38(10): 997-1002. |
[12] | 陈雪薇, 李一荣. 基于GEO数据库筛选代谢综合征潜在生物标志物[J]. 检验医学, 2023, 38(1): 32-38. |
[13] | 吴亚婷, 李卓林, 雷艳, 贾如雪, 张胜行, 王水良. 尿液中miRNA作为常见恶性肿瘤生物标志物研究进展[J]. 检验医学, 2023, 38(1): 94-99. |
[14] | 聂甜, 冉子涵, 金磊. 白细胞介素基因多态性与胃癌的相关性研究进展[J]. 检验医学, 2022, 37(9): 882-886. |
[15] | 邬燕倩, 俞翀, 沈鹭, 郑浩然, 洪叶挺. 体液piRNA作为疾病潜在生物标志物的研究进展[J]. 检验医学, 2022, 37(8): 782-786. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||